Search All UT System Experts

Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates

Leonard E. Weisman, Helen M. Thackray, Joseph A. Garcia-Prats, Mirjana Nesin, Joseph H. Schneider, Jennifer Fretz, John F. Kokai-Kun, James J. Mond, William G. Kramer, Gerald W. Fischer

Research output: Contribution to journal › Article › peer-review

70 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates'. Together they form a unique fingerprint.

Medicine & Life Sciences